|1.||Pirker, Walter: 7 articles (12/2004 - 01/2002)|
|2.||Brücke, Thomas: 5 articles (09/2005 - 01/2002)|
|3.||Brücke, T: 5 articles (07/2002 - 03/2000)|
|4.||Pirker, W: 5 articles (07/2002 - 03/2000)|
|5.||Asenbaum, S: 5 articles (02/2001 - 03/2000)|
|6.||Barthel, Henryk: 4 articles (01/2006 - 08/2002)|
|7.||Sabri, Osama: 4 articles (01/2006 - 08/2002)|
|8.||Hesse, Swen: 4 articles (01/2006 - 08/2002)|
|9.||Asenbaum, Susanne: 4 articles (11/2003 - 01/2002)|
|10.||Gerschlager, Willibald: 4 articles (11/2003 - 01/2002)|
03/01/2014 - "[(123)I]-Beta-CIT reduction was associated with BDI reduction (r(2)=0.54; F=8.8; p=0.004), but not flushing reduction or perfusion reduction. "
03/01/2014 - "Following treatment with venlafaxine, there was a significant reduction in the [(123)I]-beta-CIT binding ratio, BDI scores, flushing and endothelial dependent perfusion response. "
03/01/2014 - "Venlafaxine alters microvascular perfusion, [¹²³I]-beta-CIT binding and BDI scores in flushing postmenopausal women."
|2.||Body Weight (Weight, Body)
01/01/1995 - "A highly significant reduction of beta-CIT binding was found in an area including mesial thalamus, hypothalamus, midbrain and pons in patients under citalopram compared to controls (44.1 +/- 14.4 vs. 82.3 +/- 18.6cpm's/mCi x kg body weight; specific binding 4 hrs p.inj.; p = 0.0001). "
|3.||Parkinson Disease (Parkinson's Disease)
01/01/2003 - "We used single photon emission computed tomography (SPECT) to study striatal [(123)I]beta-CIT binding and polysomnography to study periodic leg movements during sleep (PLMS) in eleven patients with idiopathic Parkinson's disease (PD). "
07/01/1999 - "Detection of preclinical Parkinson disease in at-risk family members with use of [123I]beta-CIT and SPECT: an exploratory study."
02/01/1997 - "[123I]beta-CIT single photon emission computed tomography (SPECT) studies have demonstrated this loss of striatal DA transporter content in Parkinson's disease in vivo. "
10/01/1995 - "Previous studies have utilized single-photon emission computed tomography (SPECT) to demonstrate decreased [123I]beta-CIT striatal uptake in idiopathic Parkinson disease (PD) patients. "
01/01/2006 - "Iodine-123 ((123)I) (2beta-carboxymethoxy-3beta-[4-iodophenyl] tropane) or ((123)I) beta-CIT is a recently developed diagnostic biomarker of Parkinson's disease that provides in vivo information about nigrostriatal degeneration. "
|4.||Parkinsonian Disorders (Parkinsonism)
12/01/2002 - "The purpose of this study was to evaluate the impact of [(123)I]-beta-CIT SPET on the diagnosis and clinical management of patients with a primary, tentative diagnosis of parkinsonism. "
08/01/2006 - "Midbrain [(123)I]beta-CIT uptake discriminated atypical parkinsonian disorders from PD with an overall correct classification of 91.3%. "
08/01/2006 - "All patients with the different parkinsonian disorders showed a significant decrease in striatal [(123)I]beta-CIT uptake without any overlap with the control group. "
07/01/2005 - "We suggest that the quantification of midbrain DAT signal should be included in the routine clinical analysis of [123I]beta-CIT SPECT in patients with uncertain parkinsonism."
10/01/2004 - "Bilateral akinetic-rigid parkinsonism was found in only one patient whose [(123)I]beta-CIT-SPECT showed a decrease of the ligand uptake following the limits of the vascular lesion. "
|5.||Multiple System Atrophy
11/01/2001 - "This study has examined and compared the loss of striatal DAT in PD and multiple system atrophy (MSA) using [(123)I]beta-CIT SPECT imaging. "
07/01/2005 - "Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease."
11/01/2000 - "[123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration."
07/01/2005 - "To investigate the cerebral dopamine transporter status in the early stages of the parkinson-variant of multiple system atrophy (MSA-P), 15 patients with MSA-P and a disease duration up to 3 years were studied with [123I]beta-CIT single photon emission computed tomography (SPECT). "
01/01/2000 - "SPECT scans were acquired in 9 patients with sOPCA, 7 multiple system atrophy (MSA) patients with parkinsonism (MSA-P), and 7 age-matched healthy controls 20-24 h after the intravenous injection of [(123)I]beta-CIT. "
|4.||Serotonin (5 Hydroxytryptamine)
|5.||Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)
|6.||Cocaine (Cocaine HCl)
|7.||Levodopa (L Dopa)
|9.||3- iodo- 2- hydroxy- 6- methoxy- N- ((1- ethyl- 2- pyrrolidinyl)methyl)benzamide
|2.||Activities of Daily Living (ADL)
|3.||Gamma Cameras (Gamma Camera)